Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Novartis has announced a five-year commitment to the fight against malaria, saying it plans to invest more than $100m to advance R&D of next-generation drugs for the disease becomes resistant to ...

Kenya is among eight African countries that participated in clinical trials for a newly approved malaria treatment, ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and ...

Speaking to GSW, Krystal Birungi, a scientist at Target Malaria, said the new drug addresses a major treatment gap that has put thousands of infants at risk across Africa. According to her, the ...

The first malaria treatment specifically developed for newborn babies and young infants has been approved for use.   The approval, by Switzerland’s medical agency Swissmedic, of Coartem Baby ...

Switzerland rsquo;s recent approval of Coartem Baby, the first antimalarial treatment specifically designed for newborns and ...

Malaria research. Read the latest medical research on malaria, including new control methods and malaria treatments.